Fluid path channel and adsorbent
The patch pump integrates adsorbent-filled fluid channels to remove stabilizing agents from insulin, addressing bulkiness and inflammation issues, achieving efficient and compact insulin delivery.
Patent Information
- Application Number
- JP2024127921
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-11-20
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing patch pumps for insulin delivery are bulky, complex, and prone to inflammation at the injection site due to stabilizing compounds in insulin, necessitating a cost-effective and compact design with reduced complexity and minimized irritation.
A patch pump design featuring integrally formed fluid channels with adsorbent materials to remove stabilizing agents from insulin before delivery, utilizing a housing with separate interior regions and a barrier to maintain device integrity while minimizing size and complexity.
The design reduces insulin-related inflammation and irritation at the injection site by effectively removing stabilizing agents, ensuring consistent insulin delivery and maintaining device compactness and operational efficiency.
Smart Images

Figure 2024156879000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to medical devices, and more particularly to a drug delivery device having at least one fluid channel having an adsorbent or filter material, the channel directing a drug, such as insulin, to a delivery mechanism for delivering the drug to a patient. [Background technology]
[0002] Diabetes is a group of diseases characterized by high blood sugar levels due to the inability of diabetic patients to maintain adequate levels of insulin production when needed. If untreated, diabetes can be dangerous for affected patients, which can lead to serious health complications and early death. However, such complications can be minimized by utilizing one or more treatment options to control diabetes and reduce the risk of complications.
[0003] Treatment options for people with diabetes include diet, oral medication, and / or insulin therapy. The main goal of diabetes treatment is to control blood glucose levels in people with diabetes. However, maintaining proper diabetes control can be complicated because this must be balanced with the diabetic's activity. People with type 1 diabetes (T1D) need to take insulin (e.g., by injection or infusion) to move glucose out of the bloodstream because their bodies cannot normally produce insulin. People with type 2 diabetes (T2D) can normally produce insulin, but their bodies cannot use insulin properly to keep blood glucose levels within a medically acceptable range. In contrast to people with T1D, the majority of people with T2D do not usually require daily dosing of insulin to live. Many people are able to manage their condition with a healthy diet and increased physical activity or oral medication. However, when blood glucose levels cannot be regulated, insulin is prescribed. For example, an estimated 6.2 million people with type 2 diabetes (e.g., in the United States, Western Europe, and Canada) use a multiple-dose insulin (MDI) regimen consisting of a 24-hour basal insulin and short-acting rapid insulin taken at mealtimes to control glycemic control.
[0004] There are two basic methods of daily insulin therapy for the treatment of type 1 diabetes (T1D), and sometimes type 2 diabetes (T2D). In the first method, a diabetic self-injects insulin when needed using a syringe or insulin pen. This method requires a needle stick for each injection, and a diabetic may need three to four injections each day. The syringes and insulin pens used to inject insulin are relatively easy to use and cost-effective.
[0005] Another effective method for managing insulin therapy and diabetes is infusion therapy, or infusion pump therapy, in which an insulin pump is used. Insulin pumps can provide a continuous infusion of insulin to a diabetic patient at a variable rate to more closely match the function and behavior of a properly operating pancreas in a non-diabetic person that produces the required insulin, and the insulin pump can help a diabetic patient maintain their blood glucose level within a target range based on the individual needs of the diabetic patient. Infusion pump therapy requires an infusion cannula or flexible catheter, typically in the form of an infusion needle, that pierces the diabetic patient's skin and through which the insulin infusion is delivered. Infusion pump therapy offers the advantages of continuous infusion of insulin, precise dosing, and programmable delivery schedules.
[0006] In infusion therapy, insulin doses are typically administered at basal and bolus rates. When insulin is administered at a basal rate, it is delivered continuously over a 24-hour period to maintain the diabetic patient's blood glucose levels in a consistent range between meals and rest, typically overnight. Insulin pumps can also be programmed to vary the basal rate of insulin at different times of the day and night. In contrast, bolus doses are typically administered when the diabetic patient consumes a meal, usually providing a single additional insulin injection to balance the carbohydrates consumed. Insulin pumps can be configured to allow the diabetic patient to program the volume of the bolus dose according to the size or type of meal consumed by the diabetic patient. In addition, insulin pumps can also be configured to allow the diabetic patient to inject a correction or supplemental bolus dose of insulin to compensate for low blood glucose levels when the diabetic patient is calculating the bolus dose for a particular meal to be consumed.
[0007] Insulin pumps advantageously deliver insulin over time, rather than a single injection, typically resulting in less fluctuation within the recommended blood glucose range. In addition, insulin pumps can reduce the number of needle sticks that diabetic patients must endure, improving diabetic management and improving the quality of life of diabetic patients. For example, many T2D patients prescribed insulin therapy can be expected to switch from injection to infusion therapy due to unmet clinical need for improved control. That is, many T2D patients who use multiple injections (MDI) do not achieve target glucose control or do not adhere well to the prescribed insulin therapy.
[0008] Typically, whether a diabetic uses a multiple dose injection (MDI) or a pump, the diabetic will administer fasting glucose medication (FBGM) upon awakening from sleep and will also test blood glucose during or after each meal to determine if a correction dose is needed. In addition, a diabetic may test blood glucose before sleep to determine if a correction dose is needed, for example, after eating a snack before sleep.
[0009] To facilitate infusion therapy, there are typically two types of insulin pumps: conventional pumps and patch pumps. Conventional pumps use disposable elements, typically called an infusion set, tubing set, or pump set, that carry insulin from a reservoir in the pump to the user's skin. The infusion set includes a pump connector, a length of tubing, and a hub or base from which extends a cannula in the form of a hollow metal infusion needle or a flexible plastic catheter. The base usually has an adhesive that holds the base to the skin surface during use. The cannula may be inserted into the skin manually or by using a manual or automatic insertion device. The insertion device can be a separate unit used by the user.
[0010] Another type of insulin pump is the patch pump. Unlike a traditional infusion pump and infusion set combination, a patch pump is an integrated device that combines most or all of the fluid components in a single housing. Typically, the housing is adhesively attached to the infusion site on the patient's skin, eliminating the need for a separate infusion set or tubing set. The insulin-containing patch pump is adhered to the skin and delivers insulin over a period of time through an integrated subcutaneous cannula. Some patch pumps can wirelessly communicate with a separate controller device (such as one device sold by Insulet Corporation under the trade name OmniPod®), while others are completely self-contained. Such patch pumps are replaced frequently, such as every three days, or when the insulin reservoir is depleted. Otherwise, problems such as restrictions in the cannula or infusion site can occur.
[0011] Because the patch pump is designed to be a self-contained unit worn by the patient, the patch pump is preferably small so that it does not interfere with the user's activities. Therefore, it is preferable to minimize the overall thickness of the patch pump in order to minimize the user's discomfort. However, to minimize the thickness of the patch pump, the size of its components must be reduced as much as possible.
[0012] In current patch pump designs, tubes, such as plastic tubes, are employed as fluid paths to route fluid flow from one internal component to another. For example, tubes connect a drug reservoir to a delivery needle, but the space required to accommodate such tubes internally adds to the overall size of the patch pump. The use of tubes can increase costs and, as a result, can add complexity during an automated device assembly process. For example, such device assembly includes connecting tubes together, which adds a step to the assembly process. In addition, preventing leakage from such connections can pose additional challenges. Summary of the Invention [Problem to be solved by the invention]
[0013] Thus, a need exists for improved flow path designs for use in limited space environments, such as patch pump devices, that can deliver medication in a cost-effective manner while minimizing or reducing the overall size and complexity of the device. [Means for solving the problem]
[0014] A feature of the invention provides a delivery device, such as a patch pump, having at least one fluid channel for administering a drug to a patient, the fluid channel having a filter material to remove at least a portion of a stabilizer compound from the drug prior to delivery to the patient. In one embodiment, the fluid channel provides a bypass from a wet interface to a dry interface, minimizing complexity by routing flow away from a unique interface.
[0015] Aspects of the invention may be accomplished by providing a device for delivering a medicament to a patient's skin, the device having a housing including a reservoir for containing the medicament. A first interior region sealed from fluid intrusion may include one or more components of the delivery device. A second interior region not sealed from fluid intrusion may include one or more components of the delivery device. The housing may have a barrier separating the first interior region and the second interior region. A delivery cannula delivers the medicament to the patient's skin. In one embodiment, a base has a bottom surface for orientation toward the patient's skin. The bottom surface of the base has one or more integrally formed fluid channels disposed therein. At least one of the fluid channels contains an adsorbent or filter material in fluid communication with the delivery cannula.
[0016] The delivery device has a housing and a base that seals the housing to form an internal cavity for receiving the working components for the delivery device. The delivery device is particularly suitable for delivering insulin at a controlled rate to a patient through a cannula or catheter. Although the delivery device is shown as a patch pump or an infusion pump, the delivery device can have other forms. At least one surface of the housing or base has an integrally formed fluid channel with a filter material containing an adsorbent positioned therein. The channel delivers insulin from one component to the cannula or catheter, where insulin passing through the channel contacts the adsorbent to remove at least a portion of the stabilizing agent or stabilizing compound present in the insulin before introducing the insulin into the patient. By reducing the concentration of the stabilizing compound in the insulin before introduction into the patient, inflammation and irritation at the injection or infusion site in the patient that frequently occurs after prolonged delivery of insulin at a single injection site is reduced or inhibited.
[0017] The fluid channels may be formed as open channels molded onto a surface of the base of the device. The fluid channels have an opening at an inlet end and an opening at an outlet end that pass through the base to an opposite side of the open channels where the openings may be connected to device components and a cannula or catheter. A cover member, such as a film or layer, is applied to the surface of the base overlying the open channels to seal the open channels and form the fluid channels. The fluid channels contain a filter material containing an adsorbent, where the drug fluid contacts the adsorbent to remove at least a portion of the stabilizing agent present in the drug prior to introducing the drug into the patient.
[0018] In one embodiment, a delivery device for delivering a drug to a patient includes a housing having an open end and a base coupled to the open end and defining an interior cavity. A reservoir containing the drug is provided within the cavity of the housing. A delivery mechanism, such as a cannula or catheter, and a pump mechanism are coupled to the reservoir. The base has an integrally formed fluid channel having a flow path in fluid communication with the reservoir and the delivery mechanism. A filter material is positioned within the fluid channel to remove at least a portion of the compound from the drug prior to delivery of the drug to the delivery mechanism.
[0019] The features of the present invention are also achieved by a delivery device for delivering a medicament to a patient, the delivery device including a housing having an internal cavity and a base sealing the internal cavity. The housing has a fluid channel integrally formed with an inlet and an outlet. A reservoir is positioned within the cavity for containing the medicament, where the medicament contains a stabilizer compound. The reservoir is in fluid communication with the inlet of the fluid channel. The housing includes a delivery mechanism having a cannula for delivering the medicament to the patient, where the cannula is in fluid communication with the outlet of the fluid channel. A pump is in fluid communication with the cannula for directing the medicament from the reservoir to the cannula. The fluid channel includes a sorbent, where the medicament passing through the fluid channel contacts the sorbent to remove at least a portion of the stabilizer compound from the medicament prior to introducing the medicament to the patient.
[0020] Additional and / or other aspects and advantages of the invention will be set forth in the following description or will be apparent from the description, or may be learned by practicing the invention. The invention can include a delivery device and methods for forming and operating the same having one or more of the features and / or combinations thereof of the above-described aspects. The invention can include one or more of the features and / or combinations thereof of the above-described aspects, for example, as recited in the appended claims. [Brief description of the drawings]
[0021] Various aspects and advantages of embodiments of the present invention will be more readily understood from the following detailed description, taken in conjunction with the accompanying drawings. [Figure 1] FIG. 1 is a perspective view of a delivery device constructed in accordance with an exemplary embodiment of the present invention. [Diagram 2] FIG. 2 is an exploded view of various components of the delivery device of FIG. 1. [Diagram 3] FIG. 2 is a schematic diagram of the fluid architecture and metering subsystem diagram of the delivery device of FIG. 1. [Figure 4] FIG. 2 is a cross-sectional view of the delivery device of FIG. 1. [Diagram 5] FIG. 5 is a perspective view of the delivery device of FIG. 4 with the cover and reservoir omitted for clarity. [Figure 6] FIG. 2 is a bottom view of the base of the delivery device of FIG. 1 with components removed. [Figure 7] FIG. 2 is a top view of the base of the delivery device of FIG. 1 with components removed. [Figure 8] FIG. 13 is a partial cross-sectional view of a delivery device showing fluid channels. [Figure 9] FIG. 13 is a partial cross-sectional view of a delivery device showing a fluid channel connected to a reservoir. [Figure 10] FIG. 13 is a top view of a base of a delivery device in another embodiment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0022] Reference will now be made in detail to the embodiments of the invention illustrated in the accompanying drawings, in which like reference characters refer to like elements throughout the drawings. The embodiments described herein illustrate, but do not limit, the invention by reference to the drawings.
[0023] Those skilled in the art will understand that the present disclosure is not limited in scope to the details of the construction and arrangement of components described in the following description or illustrated in the figures. The embodiments herein can be practiced or performed in various ways. Additionally, the expressions and terms used herein are for the purpose of description and should not be considered limiting. The use of "including," "comprising," or "having" and variations thereof herein is meant to include the items listed thereafter and their equivalents, as well as additional items. Unless otherwise limited, the terms "connected," "coupled," and "mounted" and variations thereof herein are used broadly to include direct and indirect connections, couplings, and attachments. In addition, the terms "connected" and "coupled" and variations thereof are not limited to physical or mechanical connections or couplings. Additionally, terms such as upper, lower, bottom, and top are relative and are used to aid in the description, but are not limiting. Any of the embodiments and / or elements and features disclosed herein can be combined with one another to form various additional embodiments not specifically disclosed, so long as they are not mutually contradictory or inconsistent with one another. Terms of degree such as "substantially," "about," and "approximately" will be understood by those skilled in the art to refer to a reasonable range that includes and is near the given value, as well as ranges outside the given value, such as typical tolerances associated with the manufacture, assembly, and use of the embodiments. The term "substantially" when referring to a structure or characteristic includes the characteristic being the majority or entirety.
[0024] The exemplary embodiments are described with reference to diabetes management using insulin therapy, it is to be understood that these exemplary embodiments can be used with different medications and regimens to treat other physiological conditions other than diabetes using different drugs other than insulin.
[0025] FIG. 1 is a perspective view of an exemplary embodiment of a drug delivery device, shown as a patch pump 1. The patch pump described herein is configured to deliver insulin in the form of an insulin solution to a patient at a controlled rate. FIG. 2 is an exploded view of various components of the patch pump of FIG. 1, shown with a main cover 2. The various components of the patch pump 1 include a reservoir 4 for storing insulin, a pump 3 for pumping insulin from the reservoir 4, a power source 5 in the form of one or more batteries, an insertion mechanism 7 for inserting an insertion needle with a cannula 36 into the skin of a user, control electronics 8 in the form of a circuit board with optional communication capabilities with outside devices such as remote controls including smartphones and computers, a pair of dose buttons 6 on the cover 2 for actuating insulin doses, including bolus doses, and a base to which the various components above are attached by fasteners 10. The patch pump 1 also includes various fluid connector lines that transport the pumped insulin from the reservoir 4 to an infusion site. The cannula 36 can be a rigid or flexible cannula as known in the art.
[0026] FIG. 3 is a patch pump fluid architecture and metering subsystem diagram of a patch pump. The power storage subsystem for the patch pump includes a battery 12. The patch pump's control electronics 14 includes a microcontroller 16, sensing electronics 18, pump and valve controller 20, sensing electronics 22, and deployment electronics 24, which control the operation of the patch pump. The patch pump includes a fluid subsystem that can include a reservoir 4, a volume sensor 26 for the reservoir 4, and a reservoir fill port 28 for receiving a refill syringe 30 to refill the reservoir 4. The fluid subsystem can include a metering system with a pump and valve actuator 32 and an integrated pump and valve mechanism 34. The fluid subsystem can further include an obstruction sensor, a deployment actuator, and a cannula 36 for insertion into an injection site on the user's skin. The architecture of the patch pump is the same as or similar to that shown in FIG. 1.
[0027] 1, a wearable medical delivery device such as a patch pump 1 (e.g., an insulin delivery device (IDD)) is operable with a remote control device, hereafter referred to as a wireless control device (WC), that preferably communicates wirelessly with the pump 1. The WC can include a graphical user interface (GUI) display to provide a user visual information about the operation of the patch pump 1, such as, for example, configuration settings, an indication when a wireless connection with the patch pump is successful, and a visual indication when a dose is being delivered, among other display operations. The GUI display can include a touch screen display programmed to allow a user to provide touch inputs such as swipe to unlock, swipe to confirm a request to deliver a bolus, and select a confirm or set button, among other user interface operations.
[0028] The WC can communicate with the delivery device (e.g., patch pump 1) using any one or more of several communication interfaces. For example, a short-range radiation interface is provided to synchronize the timing of the WC and patch pump 1 to facilitate pairing at startup. Another interface employing standard Bluetooth Low Energy (BLE) and Transport and Application layers can be provided for wireless communication between the WC and patch pump 1. Non-limiting examples of application layer commands include priming, delivering a basal dose, delivering a bolus dose, canceling insulin delivery, checking the status of patch pump 1, stopping patch pump 1, and returning patch pump 1 status or information.
[0029] FIG. 4 is a cross-sectional view of a patch pump 1 according to an exemplary embodiment. The patch pump 1 has a housing 40 that forms a main cover that can be liquid-tightly or preferably air-tightly sealed to a base 42. The base 42 carries various components that are described in detail below. The air-tight seal between the housing 40 and the base 42 prevents fluid ingress and prevents other particles from passing through the seal. An embodiment of the patch pump 1 also includes a vent 44, or vent membrane, shown in FIGS. 6 and 7, to provide pressure equalization between the interior of the housing 40 and the outside atmosphere.
[0030] Embodiments of the seal between the housing 40 and the base 42 include, for example, a liquid-tight seal, an O-ring seal, or another mechanical seal, a gasket, an elastomer, a heat seal, an ultrasonic weld seal, a laser weld, a chemical bond, an adhesive, a solvent weld, or an adhesive weld. Laser welding is the preferred sealing method because when performed properly, it creates a seamless, completely gas-tight seal. The vent 44 or vent membrane continues to have a functional purpose of equalizing internal pressure and providing a sterile environment. Those skilled in the art will appreciate that other seals can be used without departing from the scope of the present invention.
[0031] 4, the housing 40 and the base 42 define an interior 46 divided into a first interior region 50 and a second interior region 52 by a wall forming a barrier 48. According to one embodiment, the barrier 48 is part of the housing 40 and is integrally formed as a unitary structure therewith. The barrier 48 is preferably sealed to a protruding rib 54 on the base 42, whereby the interface between the barrier 48 and the rib 54 is hermetically joined using a suitable sealing method. The barrier 48 separates the first interior region 50 from the second interior region 52 and protects the first interior region 50 from ingress of fluid from the second interior region. According to one embodiment, the second interior region 52 is not sealed from ingress of fluid.
[0032] The first interior region 50 includes components such as the pump 3, the force sensing resistor 32, and the electronics 18. Examples of electronics include semiconductor chips, controllers, diodes, antennas, coils, batteries, discrete components (e.g., resistors and capacitors), and circuit boards used to operate and control the patch pump 1 and operate the pump 3. As will be readily understood by those skilled in the art, it is desirable to have a dry environment for proper operation of these components, especially the electronics 18. The second interior region 52 includes the insertion mechanism 7 and the cannula 36. According to one embodiment, the insertion mechanism 7 interfaces with the patient's skin, so the second interior region 52 may not be an airtight sealed or liquid tight environment.
[0033] According to one embodiment, the components of the first interior region 50 are different from the components of the second interior region 52. Alternatively, the first interior region 50 and the second interior region 52 share some of the same components. For example, in some embodiments, a portion of the reservoir 4 is disposed within both the first interior region and the second interior region. When the reservoir and the insertion mechanism 7 are separated by a barrier 48, the two interior regions are in fluid communication for effective operation of the patch pump 1 and transfer of fluid from the reservoir and the pump mechanism.
[0034] 5 shows some of the major components of patch pump 1 in a perspective view with the main cover and reservoir 4 removed for clarity. According to one embodiment, a fill port 56 is coupled to a conduit for supplying drug to reservoir 4. The fill port 56 can be disposed in the first interior region 50 or the second interior region 52, but is typically located in the first interior region 50. In some embodiments, the fill port 56 includes a portion that serves as part of a flow path for drug exiting reservoir 4.
[0035] FIG. 6 shows the bottom surface 58 of the base 42 of the patch pump 1. In use, the bottom surface 58 is oriented towards the patient's skin. In some embodiments, the bottom surface 58 includes an adhesive that removably attaches the base to the patient's skin. Alternatively, an adhesive pad 60 as shown in FIG. 1 adheres to both the bottom surface 58 and the patient's skin. Typically, 3M™ Medical Tape (e.g., Product No. 1776) is the adhesive used, although various types of known industrial adhesives can be used. The adhesive is selected to ensure compatibility with human skin to prevent undesirable reactions. Also, compatibility of the adhesive and insulin is considered in case the adhesive and insulin are accidentally mixed.
[0036] As shown in FIG. 6, the bottom surface 58 of the base 42 includes at least one recess for forming a fluid channel through the base 48 from a first location to a second location. The recess forming the fluid channel can have a substantially U-shape or groove shape with a longitudinal dimension and an open side facing outwardly from the bottom surface 58. In the illustrated embodiment, a first fluid channel 62 and a second fluid channel 64 are provided. The fluid channels extend longitudinally parallel to the plane of the base 42 and are configured and positioned to direct fluid from one location within the device to a second location within the device. In the illustrated embodiment, the first fluid channel 62 is formed by a recess having an inlet end 66 and an outlet end 68. The first fluid channel 62 is typically molded into the bottom surface 58 and is covered by a cover member 70 to seal the channel and form a fluid-tight path for fluid passing through the channel. The cover 70 can be a thin flexible membrane, sheet, or film bonded to the bottom surface 58, thereby overlapping and covering the channel to form a fluid-tight pathway for the agent as shown in FIG. 6. As shown in FIG. 7, the outlet end 68 of the channel 62 includes an opening 72 passing through the base 42 between the bottom surface 58 and the top surface 74. A fitting 76 is formed on the top surface 74 where an opening passes through the fitting. The fitting 76 has an open end portion for receiving a flexible conduit 78 as shown in FIG. 5. In the illustrated embodiment, the conduit 78 extends from the outlet end 68 of the channel 62 between the cannula 36 of the insertion mechanism for supplying the agent to the cannula and delivering it to the patient. As used herein, a cannula refers to a delivery device having a lumen for introducing an agent into a patient. The cannula can be a hollow steel cannula or a flexible catheter as known in the art.
[0037] The inlet end 66 of the channel 62 also includes an opening 80 extending between the bottom surface 58 and the top surface 74 that forms a flow path between the top and bottom surfaces. A fitting 82 is on the top surface 74 and communicates with the opening 80 and the channel 62. In the illustrated embodiment, the fitting 82 receives a conduit extending between the pump 32 and the channel 62 for supplying a drug through the channel. In the illustrated embodiment, the channel 62 extends parallel to the plane of the base 42 with a fluid opening in the top surface 74 of the base 42 to direct fluid between two spaced apart locations on the top surface of the base. The channel 62 is positioned and has a length to provide fluid communication between the actuating components of the delivery device located within the cavity of the housing 40. In one embodiment, the channel 62 is oriented or positioned such that the inlet end 66 and the outlet end 68 are on opposite sides of the barrier 48 to provide fluid communication between the first interior region 50 and the second interior region 52.
[0038] 6, the channel 62 has a first section 84 and a second section 86, and an enlarged recessed area 88 between the first section 84 and the second section 86. The first and second sections have a first inner diameter sufficient to convey a medication, such as insulin, to the cannula 36 at a rate effective to introduce the medication into the patient. The recessed area 88 in the illustrated embodiment has a larger cross-section and diameter than the first and second sections. A filter material 90 is contained within the recessed area and fills the recessed area in an amount sufficient to filter and / or treat fluid passing through the channel 62.
[0039] The filter material 90 includes or contains a sorbent material capable of absorbing and removing at least a portion of one or more components from the fluid passing through the channel 62. Examples of suitable sorbent materials include carbon materials, charcoal, activated charcoal, and mixtures thereof. The filter material 90 can be a sorbent in the form of beads, powder, pellets, or extruded shapes. The filter material 90 can be made from a sorbent material or can be a support structure that includes or contains a sorbent material. The sorbent can remove a sufficient amount of stabilizers in the pharmaceutical agent to inhibit irritation and / or inflammation at the patient's delivery site without impeding or restricting the flow of the pharmaceutical agent through the channel under normal operating conditions of the pump.
[0040] The delivery device is particularly suited for delivering insulin to a patient over an extended period of time. The delivery device is actuated to insert the cannula 36 into the patient. The pump is actuated to convey insulin from the reservoir 4 to the cannula 36 where the insulin is introduced to the patient. Insulin solutions typically contain stabilizers and preservatives and these compounds to extend the useful life of the insulin before introduction to the patient. Commonly used preservatives and stabilizers include phenol and m-cresol, which are effective in extending the shelf life of insulin. Phenol, m-cresol, and other stabilizers are effective for stabilizing insulin, but often cause irritation and inflammation at the injection site after a period of time and prolonged use. Infusion devices such as patch pumps that provide sustained delivery of insulin for several days are particularly prone to irritation and inflammation at the injection site, which may be caused by stabilizing compounds in the insulin solution. Irritation and inflammation at the injection site can result in loss of insulin absorption and reduced effectiveness in maintaining desired insulin and glucose levels in the patient. The adsorbent is selected to remove at least a portion of the stabilizer without interfering with the effectiveness of the insulin.
[0041] In an embodiment of the device, a sorbent is provided or placed in the insulin flow path to remove the stabilizer prior to the introduction of the insulin to the patient, within a time period where the absence of the stabilizer in the insulin will not cause degradation of the insulin prior to introduction to the patient. In the illustrated embodiment, the sorbent is located between the pump and the cannula to contact the insulin and remove at least a portion of the stabilizer prior to delivery of the insulin to the cannula and prior to introduction to the patient. Alternatively, the sorbent may be positioned prior to or upstream of the pump mechanism. By reducing the amount of stabilizer, such as phenol and / or m-cresol, from the insulin immediately prior to or prior to introduction to the patient, the occurrence of irritation and inflammation caused by the stabilizer at the delivery or infusion site can be reduced and / or inhibited. Preferably, the sorbent reduces the concentration of stabilizer present in the insulin to reduce or eliminate irritation at the infusion site caused by the stabilizer. The sorbent is located near the cannula or catheter so that the insulin is delivered to the patient within a time period where degradation of the insulin is minimized. In one embodiment, the sorbent can remove all or a substantial portion of the stabilizer from the insulin. The amount of stabilizer removed from the insulin can be controlled by the particular sorbent, the volume or amount of sorbent relative to the volume of insulin passing through the channel, the contact time of the insulin with the sorbent, and the flow rate of the insulin through the sorbent. Typically, the sorbent can remove an amount of phenol or m-cresol, or other stabilizer, to inhibit irritation and / or inflammation caused by phenol or m-cresol at the delivery site within the patient.
[0042] The recessed area 88 preferably contains a sufficient amount of sorbent within the flow path of the channel 62 so that the agent, such as insulin, passes through the sorbent before proceeding to the cannula. The channel is shown as having an enlarged recessed area between the first and second sections. In other embodiments, the recessed area and sorbent can be located at the outlet or inlet end of the channel 62. In further embodiments, the entire channel can be filled with sorbent and the channel can have a uniform width or diameter extending between the inlet and outlet ends. The cover member 70 is attached to the bottom surface of the base 42 to retain the sorbent within the recessed area and define a flow path for the fluid through the channel 62. The filter material and / or sorbent are typically porous to remove an effective amount of the stabilizing agent to inhibit inflammation at the insulin delivery site.
[0043] As shown in Figure 7, the upper surface 74 of the base 42 is formed with various posts and mounting structures 91 to support various working components of the delivery device, such as the pump, printed circuit board, reservoir and as shown in Figures 4 and 5. An opening 93 is shown at one end for receiving the cannulation mechanism 7. Components of Figures 4 and 5 are not shown for clarity.
[0044] FIG. 8 is a side view of a partial cross section of the delivery device showing the channel 62 sealed by the cover member 70 and the filter material 90 with the sorbent contained in the flow path within the channel 62. A fitting 76 is shown connected to a flexible conduit 78 leading to the insertion mechanism and the cannula. In FIG. 8, the insertion mechanism is shown in an actuated position and the cannula 36 is inserted into the patient's skin. A fitting 82 at the inlet end of the channel 62 is shown connected to a conduit 92 that extends to the pump 32. The filter material and sorbent 90 in this embodiment are positioned between the pump 32 and the cannula 36 so that a drug such as insulin passes through the sorbent before reaching the cannula to remove at least a portion of the stabilizing agent before introducing the insulin to the patient. As shown in FIG. 8, the fluid channel extends below the barrier 48 between the first interior region 50 and the second interior region 52. In this manner, the fluid channel can carry a fluid or drug between the regions 50 and 52 without passing directly through the barrier 48.
[0045] A second channel 64, shown in FIG. 6, is also formed in the bottom surface 58 of the base 42 and is formed with an inlet end 94 and an outlet end 96. The second channel 64 is molded in the bottom surface to have sufficient dimensions to carry a drug, such as insulin, from one location to another within the device and from one working component to another. The channel 64 has an opening 98 at the inlet end 94 that extends from the base 42 to the top surface, to a fitting 100. The outlet end includes an opening 102 that extends through the base 42 to a fitting 104. As shown in FIG. 9, a cover member 70 overlies the channel 64 and seals the channel. The cover 70 is shown as a single film that covers the channels 62 and 64. Alternatively, each channel 62 and 64 may be sealed by a separate cover member. A conduit 106 extends between the fitting 100 and the reservoir 4 to carry the drug from the reservoir to the channel 64. A conduit 108 is connected to fitting 104 at the outlet end of channel 64 and is connected to a pump. In use, the pump is actuated to pump drug from reservoir 4, through conduit 106, through channel 64 and through conduit 108 to the pump. The pump then directs the drug through conduit 92 to first channel 62 and through the sorbent of filter material 90 where the processed drug is directed through conduit 78 connected to a cannula. The processed drug is then directed to the cannula for delivery to the patient.
[0046] In another embodiment shown in FIG. 10, the bottom surface of the base 42 includes fluid channels 110 and 112 formed therein similar to the embodiment of FIG. 6. The fluid channels 110 and 112 are in fluid communication with the reservoir, pump, and cannula as in the previous embodiment to carry the drug from the reservoir to the cannula. A cover member 114 is placed over the channels to seal the fluid channels to direct the fluid through the channels. In the illustrated embodiment, the channel 110 includes a recessed area 116 that includes a filter material containing an adsorbent 118, such that the fluid drug passing through the channel 110 contacts the adsorbent to remove a portion of the stabilizer compound in the drug. As in the previous embodiment, the channel 110 is in fluid communication with the pump and cannula to direct the processed fluid to the cannula. A second channel 112 is formed in a similar manner and includes an enlarged recessed area 120 for a filter material 122 containing an adsorbent. A second channel 112 is in fluid communication with the pump and reservoir as in the previous embodiment to process the fluid medication after it is removed from the reservoir and before it is conveyed to the cannula for delivery to the patient.
[0047] The fluid channels are recessed (or engraved) from the bottom surface of the base by a molding process such as injection molding, or by a cutting process such as milling. In other embodiments, the fluid channels are disposed on the main cover of the housing, or on the base 42 within the inner cavity of the housing 40. Similar fluid channels may be positioned in multiple locations within the device.
[0048] The cross-sectional shape and dimensions of the fluid channels are dictated by the desired flow characteristics. The geometry of the fluid channels is selected based on factors such as cost, manufacturability, and the desired application. Exemplary cross-sectional shapes of the fluid channels include square, rectangular, and semicircular. Those skilled in the art will appreciate that other cross-sectional shapes can be used without departing from the scope of the invention.
[0049] Preferably, the fluid channel is sized to allow unrestricted flow of the drug fluid. A pump coupled to the fluid channel controls and determines the flow rate of the drug fluid instead of the size of the fluid channel. When the fluid channel is too small, capillary action can occur, potentially resulting in obstruction of the flow of the drug fluid. Preferably, the cross-sectional area of the fluid channel is larger than the gauge of the cannula 36.
[0050] In one embodiment, the film channel cover 70 is made from a foil available from Oliver-Tolas Healthcare Packaging (e.g., TPC-0777A foil). Preferably, the film channel cover 70 is made from Oliver-Tolas Healthcare Packaging IDT-6187 transparent film and is heat sealed or heat staked to the bottom surface of the base 42 to seal the fluid channels. For example, laser welding applies a laser beam through the transparent film to secure the film channel cover 70 to the bottom surface of the base 42. Laser welding is advantageous because during the welding process, the laser can straddle the channel edges of the fluid channels and bond the film to the base 42 in areas closer to the channel edges than other methods.
[0051] The sealed fluid channel covers 70 encapsulate and protect the agent from contaminants while it is traveling through the fluid channels. When the fluid channels are disposed within the interior cavity of the housing 42 as described above, one or more fluid channel covers 70 may be suitably disposed within the upper surface of the base 42.
[0052] According to one embodiment, the medicament exits the first interior region 50 of the housing 40 through an opening in the base 42 and enters the first fluid channel 62 in the bottom surface 58 of the base 42. The medicament then travels through the interior of the housing 40 to enter the second interior region 52 via a fluid channel passage disposed at a first end of the first fluid channel 62. By routing the medicament through the first fluid channel 62 outside the interior of the housing, the first fluid channel 62 advantageously and effectively bypasses the barrier 48. The first fluid channel establishes fluid communication between the pump 3 and the cannula 47 while bypassing the barrier 49, thereby maintaining the integrity of the barrier 48. The first fluid channel 62 provides fluid communication between the first interior region 50, which is sealed from fluid ingress, and the second interior region 52, which is not sealed from fluid ingress, without compromising the integrity of the barrier 48.
[0053] Although only a few embodiments of the present invention have been shown and described, the device of the present invention is not limited to the described embodiments. Instead, it will be understood by those skilled in the art that modifications may be made to these embodiments without departing from the principle and spirit of the device. Various embodiments may be combined with other embodiments as long as they are not inconsistent with each other. It is particularly noted that those skilled in the art can easily combine various technical aspects of various elements of the various exemplary embodiments described above in numerous other ways, all of which are considered to be within the scope of the present disclosure and its equivalents.
Claims
1. A delivery device for a medicament, comprising: a housing having an open end; a base coupled to the open end of the housing and defining an interior cavity; a reservoir within said cavity for containing said agent; a delivery mechanism for delivering the agent to a patient; a pump mechanism for delivering the agent from the reservoir to the delivery mechanism; an integrally formed fluid channel in the base, the fluid channel having a flow path in fluid communication with the reservoir and the delivery mechanism; a filter material positioned within the fluid channel to contact the agent and remove at least a portion of a compound from the agent prior to delivery of the agent to the delivery mechanism; A delivery device comprising:
2. 10. The delivery device of claim 1, wherein the compound is a stabilizing agent, and the filter material removes at least a portion of the stabilizing agent from the drug prior to delivering the drug to the patient.
3. 3. The delivery device of claim 2, wherein the medication is an insulin solution, the stabilizing agent is selected from the group consisting of m-cresol, phenol, and mixtures thereof, and the filter material is included in an amount effective to remove at least a portion of the stabilizing agent to inhibit irritation at the delivery side of the delivery mechanism.
4. 3. The delivery device of claim 2, wherein the filter material comprises an adsorbent selected from the group consisting of carbon, charcoal, activated charcoal, and mixtures thereof.
5. The delivery device of claim 1 , wherein the base has a bottom surface with an open channel and a cover that covers and seals the open channel to define the fluid channel.
6. The delivery device of claim 5 , wherein the cover is a foil bonded to the bottom surface of the base.
7. The delivery device of claim 5 , wherein the fluid channel has an inlet end in fluid communication with the pump and an outlet end in fluid communication with the delivery mechanism.
8. 8. The delivery device of claim 7, wherein the delivery mechanism includes a cannula having a distal end for penetrating the patient's skin and a proximal end, and a conduit extending between the proximal end of the cannula and the outlet end of the fluid channel.
9. The delivery device of claim 8 , wherein the filter element is positioned in the fluid channel between the cannula and the pump mechanism.
10. 6. The delivery device of claim 5, wherein the fluid channel has a first section having a first inner diameter and a recess having a second inner diameter larger than the first inner diameter, and the filter material is positioned within the recess.
11. 6. The delivery device of claim 5, wherein the housing further comprises a barrier defining a first interior region and a second interior region, the fluid channel extending between the first interior region and the second interior region.
12. 1. A delivery device for delivering a medicament to a patient, comprising: a housing having an internal cavity and a base sealing said cavity, said housing having an integrally formed fluid channel having an inlet and an outlet; a reservoir within the cavity for containing the agent, the agent including a stabilizing agent, the reservoir in fluid communication with the inlet of the fluid channel; a delivery mechanism having a cannula for delivering the agent to the patient, the cannula in fluid communication with the outlet of the fluid channel; a pump in fluid communication with the cannula for directing the agent from the reservoir to the cannula; an adsorbent in the fluid channel, the drug passing through the fluid channel contacting the adsorbent to remove at least a portion of the stabilizer compound from the drug; A delivery device comprising:
13. 13. The delivery device of claim 12, wherein the medication is an insulin solution, the stabilizing agent is selected from the group consisting of m-cresol, phenol, and mixtures thereof, and the adsorbent is included in an amount effective to remove at least a portion of the stabilizing agent to inhibit irritation at the delivery side of the delivery mechanism.
14. 14. The delivery device of claim 13, wherein the adsorbent is selected from the group consisting of carbon, charcoal, activated charcoal, and mixtures thereof, and the adsorbent is included in an amount to remove at least a portion of the stabilizing agent passing through the fluid channel.
15. The delivery device of claim 12 , wherein the base has an inner surface facing the cavity and an outer surface having an open channel defining the fluid channel, and a cover covering and sealing the open channel.
16. The device of claim 15 , wherein the cover comprises a foil attached to the base.
17. The device of claim 12 , wherein the inlet of the fluid channel is in fluid communication with the pump and the outlet is in fluid communication with the cannula.
18. 16. The delivery device of claim 15, wherein the base has a first fitting having a fluid passage communicating with the inlet of the fluid channel and a conduit coupled to the first fitting, and a second fitting having a fluid passage communicating with the outlet of the fluid channel and a conduit coupled to the second fitting and coupled to the cannula, and the adsorbent is positioned between the pump and the cannula to remove at least a portion of the stabilizer compound from the drug.
19. 13. The delivery device of claim 12, wherein the fluid channel has a first section having a first inner diameter and a recess having a second inner diameter larger than the first diameter, and the adsorbent is disposed within the recess.
20. 20. The delivery device of claim 19, wherein the fluid channel has a first section having a first inner diameter and a recess having a second inner diameter larger than the first inner diameter, and the filter material is positioned within the recess.
21. 1. A drug delivery device comprising: a housing having an internal cavity, the housing having a base with an integral fluid channel formed in the base and a sorbent within the fluid channel in contact with the drug; a delivery mechanism for delivering the drug to a patient, the fluid channel being in fluid communication with the delivery mechanism for delivering the drug to the delivery mechanism, the drug passing through the adsorbent to remove at least a portion of a stabilizer compound in the drug; A drug delivery device comprising:
22. 22. The drug delivery device of claim 21, wherein the base has an outer surface with an open channel and a cover that covers and seals the open channel to define the fluid channel, and the housing further comprises a barrier defining a first interior region and a second interior region, and the fluid channel extends between the first interior region and the second interior region.
Citation Information
Patent Citations
Fluid delivery device with temperature controlled energy source
JP2001513409A
Drug delivery device with bolus injection site
JP2001515371A
Plate with integrated fluidic channels
JP2017534328A
Infusion set with components comprising a polymeric sorbent to reduce the concentration of m-cresol in insulin
WO2017184985A1
Filter for reducing phenolic compounds from insulin and related infusion and injection devices
WO2018204327A1
